RGC Fundamental Analysis - REGENCELL BIOSCIENCE HOLDING

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to RGC. RGC was compared to 193 industry peers in the Pharmaceuticals industry. While RGC has a great health rating, there are worries on its profitability. RGC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

RGC had negative earnings in the past year.

RGC had a negative operating cash flow in the past year.

In the past 5 years RGC always reported negative net income.

RGC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RGC has a Return On Assets (-51.07%) which is comparable to the rest of the industry.

Looking at the Return On Equity, with a value of -52.43%, RGC is in line with its industry, outperforming 53.89% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-51.07%
ROE	-52.43%
ROIC	N/A

ROA(3y)-46.27%

ROA(5y)-138.94%

ROE(3y)-48.25%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for RGC remains at a similar level compared to 1 year ago.

The number of shares outstanding for RGC has been increased compared to 5 years ago.

RGC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RGC has an Altman-Z score of 18552.49. This indicates that RGC is financially healthy and has little risk of bankruptcy at the moment.

RGC has a Altman-Z score of 18552.49. This is amongst the best in the industry. RGC outperforms 100.00% of its industry peers.

RGC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	18552.49

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 42.68 indicates that RGC has no problem at all paying its short term obligations.

With an excellent Current ratio value of 42.68, RGC belongs to the best of the industry, outperforming 98.96% of the companies in the same industry.

RGC has a Quick Ratio of 42.68. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.

RGC has a better Quick ratio (42.68) than 98.96% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	42.68
Quick Ratio	42.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.

EPS 1Y (TTM)100%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RGC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REGENCELL BIOSCIENCE HOLDING

NASDAQ:RGC (8/5/2025, 5:25:55 PM)

After market: 13.46 0 (0%)

13.46

-0.3 (-2.18%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)12-13 2022-12-13/bmo

Inst Owners0.07%

Inst Owner Change272.84%

Ins Owners86.24%

Ins Owner Change0%

Market Cap6.66B

Analysts63.4

Price TargetN/A

Short Float %N/A

Short Ratio1.4

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	809.71
P/tB	809.71
EV/EBITDA	N/A

EPS(TTM)0

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0

BVpS0.02

TBVpS0.02

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-51.07%
ROE	-52.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-46.27%

ROA(5y)-138.94%

ROE(3y)-48.25%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	3.23%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	42.68
Quick Ratio	42.68
Altman-Z	18552.49

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)177.86%

Cap/Depr(5y)346.71%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)100%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y24.56%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y19.64%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y19.35%

OCF growth 3YN/A

OCF growth 5YN/A

REGENCELL BIOSCIENCE HOLDING (RGC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens